Stefan K James

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
  2. ncbi Diagnostic applications of natriuretic peptides in ischemic heart disease
    Bertil Lindahl
    University Hospital of Uppsala, Uppsala, Sweden
    Heart Fail Clin 2:311-21. 2006
  3. ncbi Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy
    Stefan K James
    Uppsala Clinical Research Center, Uppsala, Sweden
    J Am Coll Cardiol 48:1146-54. 2006
  4. ncbi Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy)
    Stefan K James
    Department of Medical Sciences and Cardiology, Academic Hospital, Uppsala, Sweden
    Am J Cardiol 97:167-72. 2006
  5. ncbi An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
  6. ncbi Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin
    Stefan James
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Ups J Med Sci 109:71-122. 2004
  7. ncbi [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
    Stefan James
    Kardiologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 101:1514-9, 1521-2. 2004
  8. ncbi Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden
    Stefan K James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 360:1933-45. 2009
  9. ncbi Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy
    Stefan K James
    Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Am Heart J 147:267-74. 2004
  10. ncbi N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (
    Stefan K James
    Department of Medical Sciences, Cardiology, University of Uppsala, Uppsala, Sweden
    Circulation 108:275-81. 2003

Detail Information

Publications39

  1. ncbi Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
    ..However, the appropriate cutoff for identifying patients with the acute coronary syndrome who are at low risk of subsequent mortality has not been established...
  2. ncbi Diagnostic applications of natriuretic peptides in ischemic heart disease
    Bertil Lindahl
    University Hospital of Uppsala, Uppsala, Sweden
    Heart Fail Clin 2:311-21. 2006
  3. ncbi Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy
    Stefan K James
    Uppsala Clinical Research Center, Uppsala, Sweden
    J Am Coll Cardiol 48:1146-54. 2006
    ..This study was designed to evaluate biomarkers for selection of patients with non-ST-segment elevation acute coronary syndromes (ACS) that derive mortality benefit from revascularization...
  4. ncbi Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy)
    Stefan K James
    Department of Medical Sciences and Cardiology, Academic Hospital, Uppsala, Sweden
    Am J Cardiol 97:167-72. 2006
    ..Despite a larger proportion of ST depression and increased levels of NT-pro-BNP and interleukin-6 at admission, these factors provide independent prognostic information that may improve risk stratification and guidance of treatment...
  5. ncbi An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
    ..Inflammation plays an important role in unstable coronary artery disease (CAD). We assessed the kinetics of inflammatory markers from symptom onset in patients with unstable CAD and their relation to myocardial damage...
  6. ncbi Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin
    Stefan James
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Ups J Med Sci 109:71-122. 2004
    ..Any detectable elevation of TnT and reduced creatinine clearance, but neither elevation of CRP nor NT-proBNP, were also independently associated to a raised risk of subsequent myocardial infarction...
  7. ncbi [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
    Stefan James
    Kardiologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 101:1514-9, 1521-2. 2004
    ....
  8. ncbi Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden
    Stefan K James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 360:1933-45. 2009
    ..The long-term safety and efficacy of drug-eluting coronary stents have been questioned...
  9. ncbi Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy
    Stefan K James
    Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Am Heart J 147:267-74. 2004
    ..In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab attenuates inflammation and coagulation activity...
  10. ncbi N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (
    Stefan K James
    Department of Medical Sciences, Cardiology, University of Uppsala, Uppsala, Sweden
    Circulation 108:275-81. 2003
    ....
  11. ncbi A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes
    Stefan K James
    Department of Medical Sciences, Cardiology, Uppsala, Sweden
    Int J Cardiol 93:113-20. 2004
    ..Troponin is a specific marker of myocardial damage. For early prediction of coronary events in patients with suspicion of acute coronary syndromes the assay also needs to be highly sensitive...
  12. ncbi Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study
    Axel Akerblom
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Clin Chem 58:190-9. 2012
    ....
  13. ncbi Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry)
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    J Am Coll Cardiol 53:1660-7. 2009
    ..Our aim was to evaluate restenosis rate of drug-eluting stents (DES) in patients with and without diabetes mellitus (DM) in a real-world setting...
  14. ncbi Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy
    Stefan K James
    Department of Medical Sciences Cardiology, Thoraxcenter, Academic Hospital, 751 85 Uppsala, Sweden
    J Am Coll Cardiol 41:916-24. 2003
    ..We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS)...
  15. ncbi Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients-Results from the PLATelet inhibition and patient Outcomes (PLATO) study
    Axel Akerblom
    Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Dept of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden Electronic address
    Am Heart J 164:728-34. 2012
    ....
  16. ncbi Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
    Ulf Stenestrand
    Department of Cardiology, University Hospital, 581 85 Linkoping, Sweden
    Eur Heart J 31:177-86. 2010
    ..Patients with diabetes mellitus have more extensive coronary artery disease, more disease progression, and restenosis. The use of drug-eluting stents (DES) in these patients is widespread, despite uncertain long-term safety and efficacy...
  17. ncbi Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)
    Axel Akerblom
    Department of Cardiology, UppsalaClinical Research Center, Uppsala University, Uppsala, Sweden
    J Am Coll Cardiol 56:470-5. 2010
    ..The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)...
  18. ncbi Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden
    Bo Lagerqvist
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 356:1009-19. 2007
    ..Recent reports have indicated that there may be an increased risk of late stent thrombosis with the use of drug-eluting stents, as compared with bare-metal stents...
  19. ncbi Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry
    Bo Lagerqvist
    Uppsala Clinical Research Centre, Uppsala University Hospital, Uppsala, Sweden
    Circ Cardiovasc Interv 2:401-8. 2009
    ..The objective was to evaluate the role of risk factors and stent type for stent thrombosis (ST) using a large real world registry...
  20. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack
    Stefan K James
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Circulation 125:2914-21. 2012
    ..Patients with acute coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial hemorrhages...
  21. ncbi Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    Am Heart J 160:1042-8. 2010
    ..Thrombus aspiration is widely used in clinical practice and is recommended by international guidelines despite limited evidence...
  22. ncbi Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Sweden
    Am Heart J 164:87-93. 2012
    ..Long-term safety and efficacy data of drug-eluting stents (DESs) in saphenous vein grafts (SVGs) are lacking. This study sought to compare the clinical outcomes of DES versus bare metal stents (BMS) in SVGs...
  23. ncbi Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:699-704. 2007
    ....
  24. ncbi NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, Uppsala 751 85, Sweden
    Eur J Heart Fail 6:319-25. 2004
    ..e. unstable angina or non-ST-elevation myocardial infarction. This article focuses on the emerging role of N-terminal pro brain natriuretic peptide (NT-proBNP) and the results from the FAST, GUSTO IV and FRISC II trials...
  25. ncbi Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome
    Tomas Jernberg
    Department of Medical Sciences, Cardiology, Uppsala Research Center, University Hospital, 751 85 Uppsala, Sweden
    Circulation 110:2342-8. 2004
    ..Cystatin C is a new and better marker of renal function than creatinine. The aim was therefore to evaluate the prognostic value of cystatin C in this population...
  26. ncbi Clinical performance of two highly sensitive cardiac troponin I assays
    Per Venge
    Department of Medical Sciences, Clinical Chemistry, University of Uppsala
    Clin Chem 55:109-16. 2009
    ..The aim of this study was to compare the clinical performance of 2 sensitive cTnI assays with 10% CV imprecision below the 99th percentile upper reference limit...
  27. ncbi ST2 and mortality in non-ST-segment elevation acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Uppsala University, Sweden
    Am Heart J 159:788-94. 2010
    ....
  28. ncbi Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia
    Per Venge
    Department of Medical Sciences, University of Uppsala, Sweden
    J Am Coll Cardiol 54:1165-72. 2009
    ..This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac troponin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California)...
  29. ncbi The antibody configurations of cardiac troponin I assays may determine their clinical performance
    Stefan James
    Department of Medical Sciences, Cardiology, Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
    Clin Chem 52:832-7. 2006
    ..CONCLUSIONS: The Architect cTnI assay has clinical performance similar to that of the AccuTnI, probably as a result of the inclusion of a monoclonal antibody against troponin I epitope 41-49 in the assay...
  30. ncbi Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
    ..Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment...
  31. ncbi Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
    ..These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments...
  32. ncbi The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes
    Bertil Lindahl
    Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, University of Uppsala, Uppsala, Sweden
    Am Heart J 160:224-9. 2010
    ..However, how the hs-cTnT assay compares with the old cTnT assay for risk assessment in ACS is still unknown...
  33. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan K James
    Uppsala Clinical Research Center, Uppsala University, Sweden
    BMJ 342:d3527. 2011
    ..To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy...
  34. ncbi Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
    ....
  35. ncbi Natriuretic peptides in unstable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Research Center, Sweden
    Eur Heart J 25:1486-93. 2004
    ..Before a routine use of BNP or NT-proBNP in unstable CAD can be recommended, the cost-effectiveness of adding these new markers to the currently routine markers and their impact on selection of treatment needs further evaluation...
  36. ncbi Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
    ..We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel...
  37. ncbi Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
    ..P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease...
  38. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  39. ncbi Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    David Erlinge
    Department of Cardiology, Lund University, Lund, Sweden
    J Am Coll Cardiol 52:1968-77. 2008
    ..We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes...